Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
2006
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
2006
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2007
Acute Coronary Care in the Elderly, Part I
2007
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report
2015
Acute kidney injury
2012 Standout
Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel
2007
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010 Standout
High Residual Platelet Reactivity After Clopidogrel Loading and Long-term Cardiovascular Events Among Patients With Acute Coronary Syndromes Undergoing PCI
2011
Voltage-Gated Sodium Channels: Mutations, Channelopathies and Targets
2011
Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis
2009
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)
2006
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
2007
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
2010
Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome
2007
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
2011 Standout
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin
2006
Rationale and design of the Pan-African Sudden Cardiac Death survey: the Pan-African SCD study : cardiovascular topic
2014
Variability in Individual Responsiveness to Clopidogrel
2007
Bivalirudin during Primary PCI in Acute Myocardial Infarction
2008 Standout
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association
2019
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial
2008
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
2007
Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy
2011
Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events
2009 Standout
The changing landscape of atherosclerosis
2021 StandoutNature
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
2009
The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
2005
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2008 Standout
Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients
2013 StandoutNobel
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
2010
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
2012
Current knowledge of hypertriglyceridemic pancreatitis
2014
Cardiovascular effects of gliptins
2013
Acute Pancreatitis
2016 Standout
Mitochondria: In Sickness and in Health
2012 Standout
Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes
2009
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Platelet Activation and Atherothrombosis
2007 Standout
Acute kidney injury
2019 Standout
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
2006
Pharmacology of Antiplatelet Agents
2013
Determinants of the interindividual variability in response to antiplatelet drugs
2005
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
2015
Type 2 diabetes
2017 Standout
Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
2010
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
2010
Methadone Safety: A Clinical Practice Guideline From the American Pain Society and College on Problems of Drug Dependence, in Collaboration With the Heart Rhythm Society
2014
European Resuscitation Council Guidelines for Resuscitation 2010 Section 4. Adult advanced life support
2010 Standout
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
2012
Guidelines for Percutaneous Coronary Interventions
2005
Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement
2006
Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
2008 Standout
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology
2008
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
2009
Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases
2018 Standout
Clopidogrel Loading Dose (300 Versus 600 mg) Strategies for Patients With Stable Angina Pectoris Subjected to Percutaneous Coronary Intervention
2006
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
2012
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
2006
Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis
2008
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary
2008
Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation
2006
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
2009
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2014 Standout
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis
2005
Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention
2008
Current Options in Platelet Function Testing
2006
Nonsustained Ventricular Tachycardia
2012
Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis
2007
Inflammation, metaflammation and immunometabolic disorders
2017 StandoutNature
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
2013 Standout
Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction
2018
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects
2008
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 Standout
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
Patterned Hydrogels for Controlled Platelet Adhesion from Whole Blood and Plasma
2010 StandoutNobel
HIF-1α is required for development of the sympathetic nervous system
2019 StandoutNobel
Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y 12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention
2005
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Prevention of type 2 diabetes; a systematic review and meta‐analysis of different intervention strategies
2014
Platelet Function Testing in Cardiovascular Diseases
2004
Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes
2010
Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel
2006
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes
2007
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies
2010
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
2019 Standout
Hypoglycemic agents and potential anti-inflammatory activity
2016
Modeling hepatitis C virus infection using human induced pluripotent stem cells
2012 StandoutNobel
Mendelian randomisation applied to drug development in cardiovascular disease: a review
2014
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
2016 Standout
Statins for the primary prevention of cardiovascular disease
2013
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
2018 Standout
Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets
2005
2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)
2012
Efficacy of Short-Term High-Dose Atorvastatin for Prevention of Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography
2010
Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation
2010
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
2007
Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice
2011
Epidemiology and Genetics of Sudden Cardiac Death
2012
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2008 Standout
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
2007
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel
2009
2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2012
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”
2010
2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2012
Psychosocial interventions for smoking cessation in patients with coronary heart disease
2015
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes
2015
Monitoring of Clopidogrel Action: Comparison of Methods
2005
Global burden of heart failure: a comprehensive and updated review of epidemiology
2022 Standout
Clopidogrel Response Variability and Future Therapies
2006
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2012
Weekend versus Weekday Admission and Mortality from Myocardial Infarction
2007 Standout
Hypermorphic mutation of the voltage-gated sodium channel encoding gene Scn10a causes a dramatic stimulus-dependent neurobehavioral phenotype
2011 StandoutNobel
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2013
Works of Ilan Goldenberg being referenced
Clinical Aspects of Type-1 Long-QT Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene
2007
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
2012
One-year outcome following coronary angiography in elderly patients with non-ST elevation myocardial infarction
2012
Beta‐Blocker Efficacy in High‐Risk Patients with the Congenital Long‐QT Syndrome Types 1 and 2: Implications for Patient Management
2010
Long-term Benefit of High-Density Lipoprotein Cholesterol–Raising Therapy With Bezafibrate
2009
Risk of Fatal Arrhythmic Events in Long QT Syndrome Patients After Syncope
2010
Arrhythmic and Mortality Outcomes Among Ischemic Versus Nonischemic Cardiomyopathy Patients Receiving Primary ICD Therapy
2021
Reverse Remodeling and the Risk of Ventricular Tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy)
2011
Genetics of Sudden Cardiac Death
2011
Risk Factors for Recurrent Syncope and Subsequent Fatal or Near-Fatal Events in Children and Adolescents With Long QT Syndrome
2011
Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
2012
Cardiac Resynchronization Therapy Reduces Left Atrial Volume and the Risk of Atrial Tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)
2011
Lipid-Modifying Therapies and Risk of Pancreatitis
2012
Cardiac Resynchronization Therapy Is More Effective in Women Than in Men
2011
Coronary CT angiography for the detection of coronary artery stenosis in patients referred for transcatheter aortic valve replacement
2014
Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator
2013
Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction
2003
Comparison of Statin Alone Versus Bezafibrate and Statin Combination in Patients With Diabetes Mellitus and Acute Coronary Syndrome
2013
Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies
2005
Update on the use of fibrates: focus on bezafibrate
2008
Long QT Syndrome
2008
Long QT Syndrome and Pregnancy
2007
Corrected QT Variability in Serial Electrocardiograms in Long QT Syndrome
2006
Long QT Syndrome in Adults
2007
Multidisciplinary rehabilitation program in recently hospitalized patients with heart failure and preserved ejection fraction: Rationale and design of a randomized controlled trial
2014
Risk of Aborted Cardiac Arrest or Sudden Cardiac Death During Adolescence in the Long-QT Syndrome
2006
Secondary Prevention With Bezafibrate Therapy for the Treatment of Dyslipidemia
2008
Current Smoking, Smoking Cessation, and the Risk of Sudden Cardiac Death in Patients With Coronary Artery Disease
2003
Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction
2004
Update on the use of fibrates: focus on bezafibrate
2008
Renal Dysfunction and Clinical Outcomes of Patients Undergoing ICD and CRTD Implantation: Data from the Israeli ICD Registry
2014
Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT)
2011
Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease
2016
Risk Factors for Aborted Cardiac Arrest and Sudden Cardiac Death in Children With the Congenital Long-QT Syndrome
2008
Left Ventricular Lead Position and Clinical Outcome in the Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT-CRT) Trial
2011